Flexion Therapeutics Inc (FLXN)

20.59
NASDAQ : Health Care
Prev Close 20.16
Day Low/High 19.84 / 20.65
52 Wk Low/High 13.20 / 29.41
Avg Volume 694.30K
Exchange NASDAQ
Shares Outstanding 31.76M
Market Cap 640.24M
EPS -2.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week of FLXN February 2018 Options Trading

Investors in Flexion Therapeutics, Inc. saw new options begin trading this week, for the February 2018 expiration.

Biotech Movers: Coherus, XBiotech, Flexion

Biotech Movers: Coherus, XBiotech, Flexion

Coherus BioSciences, XBiotech and Flexion Therapeutics were among the biotech stock movers in premarket trading on Monday.

Flexion Therapeutics To Present Data On Zilretta™ (FX006) At The American Diabetes Association's 77th Scientific Sessions

Full findings from Phase 2 study in patients with knee osteoarthritis and Type 2 diabetes show Zilretta avoids the significant rise in blood glucose seen with an immediate-release corticosteroid

Flexion Therapeutics is Now Oversold (FLXN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

FLXN: Insiders vs. Shorts

The most recent short interest data was recently released for the 05/15/2017 settlement date, and Flexion Therapeutics, Inc. is one of the most shorted stocks of the Russell 3000, based on 5.76 "days to cover" versus the median component at 4.71.

4 Undervalued Biotech Stocks

4 Undervalued Biotech Stocks

Two are turnaround stories, and two are oversold.

Short Interest Increases 103.8% For FLXN

The most recent short interest data has been released for the 05/15/2017 settlement date, which shows a 2,281,535 share increase in total short interest for Flexion Therapeutics, Inc. , to 4,478,675, an increase of 103.84% since 04/28/2017.

2 Oversold Biopharmas With Big 2017 Upsides

2 Oversold Biopharmas With Big 2017 Upsides

Flexion Therapeutics and BioDelivery Sciences are well below what they once fetched.

Flexion Therapeutics Announces Upcoming Data Presentation At The American Diabetes Association's 77th Scientific Sessions

Presentation to include full results from Phase 2 study evaluating Zilretta™ (FX006) in patients with Type 2 diabetes and osteoarthritis of the knee

First Week of FLXN November 17th Options Trading

Investors in Flexion Therapeutics, Inc. saw new options begin trading this week, for the November 17th expiration.

Biotech Movers: Akebia Soars on Expanded Partnership With Otsuka

Biotech Movers: Akebia Soars on Expanded Partnership With Otsuka

Akebia after the market close on Tuesday announced an expanded partnership with Japan's Otsuka Pharmaceuticals to develop and market its anemia pill Vadadustat in Europe, China and other territories.

Shark Bites: You Don't Want to Play the Gambler Today

Shark Bites: You Don't Want to Play the Gambler Today

This is one of those days when it may pay to walk away.

Second-Quarter Picks and Pans

Second-Quarter Picks and Pans

Las Vegas Sands and Flexion are in, and the autos are out.

I'm Big on Housing Entering Quarter No. 2

I'm Big on Housing Entering Quarter No. 2

Home builders make up the second-largest allocation in my portfolio, behind biotech.

How I'd Play Biotech Buyout Rumors

How I'd Play Biotech Buyout Rumors

Answering questions from the Biotech Mailbag on FLXN and SGYP.

How I'd Play Biotech Buyout Rumors

How I'd Play Biotech Buyout Rumors

Answering questions from the Biotech Mailbag on FLXN and SGYP.

Stocks Fall as House Leaders Delay Health Care Vote

Stocks Fall as House Leaders Delay Health Care Vote

Stocks fall on Thursday afternoon after House leaders delay a highly anticipated vote on the Republicans' repeal-and-replace health care bill.

Noteworthy Thursday Option Activity: FLXN, Z, SWC

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Flexion Therapeutics, Inc. , where a total volume of 1,667 contracts has been traded thus far today, a contract volume which is representative of approximately 166,700 underlying shares (given that every 1 contract represents 100 underlying shares).